RNA-binding proteins in metabolic-associated fatty liver disease (MAFLD): From mechanism to therapy

Xu, Jiawei; Liu, Xingyu; Shu-qin, WU; Zhang, Deju; Liu, Xiao; Xia, Panpan; Ling, Jitao; Zheng, Kai; Xu, Minxuan; Shen, Yue; Zhang, Jing; Yu, Peng

doi:10.5582/bst.2022.01473

Cited by 1 publication

(1 citation statement)

References 151 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This cause‐and‐effect relationship suggests that restoration of specific RBP function in diseased hepatocytes may halt or reverse the progression of hepatocellular injury and treat chronic liver disease phenotypes. Multiple approaches have been suggested that utilize the functional properties of RBPs as the basis for a therapeutic effect targeting acute and chronic liver disease phenotypes (Xu et al, 2023). We group these approaches into four categories comprising adenoviral‐induced hepatocellular RBP expression; modulation of specific RBP gene expression; direct RBP mRNA therapeutics; and drug repurposing approaches (illustrated in Figure 3).…”

Section: Post‐transcriptional Mechanismsmentioning

confidence: 99%

Emerging roles of RNA‐binding proteins in fatty liver disease

Adesanya,

Das,

Kalsotra

2024

WIREs RNA

View full text Add to dashboard Cite

A rampant and urgent global health issue of the 21st century is the emergence and progression of fatty liver disease (FLD), including alcoholic fatty liver disease and the more heterogenous metabolism‐associated (or non‐alcoholic) fatty liver disease (MAFLD/NAFLD) phenotypes. These conditions manifest as disease spectra, progressing from benign hepatic steatosis to symptomatic steatohepatitis, cirrhosis, and, ultimately, hepatocellular carcinoma. With numerous intricately regulated molecular pathways implicated in its pathophysiology, recent data have emphasized the critical roles of RNA‐binding proteins (RBPs) in the onset and development of FLD. They regulate gene transcription and post‐transcriptional processes, including pre‐mRNA splicing, capping, and polyadenylation, as well as mature mRNA transport, stability, and translation. RBP dysfunction at every point along the mRNA life cycle has been associated with altered lipid metabolism and cellular stress response, resulting in hepatic inflammation and fibrosis. Here, we discuss the current understanding of the role of RBPs in the post‐transcriptional processes associated with FLD and highlight the possible and emerging therapeutic strategies leveraging RBP function for FLD treatment.This article is categorized under: RNA in Disease and Development > RNA in Disease

show abstract

Section: Post‐transcriptional Mechanismsmentioning

confidence: 99%